Keloid
Conditions
Brief summary
Treatment of keloids with targeted Ultraviolet-Beta (UVB) radiation will improve the clinical appearance and induration of lesions.
Interventions
NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
Sponsors
Study design
Intervention model description
Each participant served as his/hers own control.
Eligibility
Inclusion criteria
* Participants must be 18 years old or over * Participants must have a diagnosis of keloid * No treatment with topical or intralesional steroids for 1 month prior to study
Exclusion criteria
* Patients who are unable to provide informed consent * A history of photosensitivity, lupus erythematosus, porphyria or current use of a known photosensitizing drug * Unwillingness to stop with topical or intralesional steroids for 1 month prior to study * A history of malignant melanoma * A history of radiation therapy to area of interest * Subjects who self-report that they are pregnant or nursing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Appearance As Assessed by the Patient and Observer Scar Assessment (POSAS) Scale | 16 weeks | Investigators will evaluate the pre- and post-study clinical photographs of all participants. The grading investigator will grade the degree of improvement using the POSAS scale to measure the clinical appearance of the keloids |